MedTrace Logo

Acute Kidney Injury After Cardiac Surgery

NCT03396770 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 848

Last updated 2021-12-02

No results posted yet for this study

Summary

Acute kidney injury (AKI) is common after cardiac surgery. The diagnosis is based on the criteria defined by the Kidney Disease Improving Global Outcomes (KDIGO) classification: oliguria and elevation of serum creatinine. However, oliguria is not specific of AKI and elevation of serum creatinine is too late. Therefore, new methods have been developed to earlier assess the risk of AKI.

Among those methods, it has been shown that the increase of urinary dosage, in the hours following the surgery, of two proteins (Tissue Inhibitor of Metallo-Protease 2 (TIMP2) and Insulin Growth Factor Binding Protein 7 (IGFBP7)) is associated with an increased risk of occurrence of AKI in patients hospitalized in intensive care unit. The Nephrocheck® test combines the urinary dosage of those two proteins TIMP2 and IGFBP7.

Insofar as post-surgery low cardiac output is one curable cause of AKI, the early detection of early kidney risk allows corrective measures to stabilize hemodynamic state and thus to reduce the risk of AKI.

Conditions

Interventions

PROCEDURE

Standard clinical routine

Patient management is carried out according to the usual service protocol

PROCEDURE

Nephrocheck test

Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass * If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated. * If the test is negative, patient management is carried out according to the usual protocol. * A second test is realized 6 hours after the first test whatever the result of it.

Sponsors & Collaborators

  • JRAR Association

    collaborator UNKNOWN

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Sébastien BIEDERMANN, MD · CHU Rennes

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-14
Primary Completion
2021-09-16
Completion
2021-09-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03396770 on ClinicalTrials.gov